In Reply On behalf of my coauthors, I am writing to reply to a reader’s query regarding the statistics of the primary efficacy end point in our article, “Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa: A Randomized Clinical Trial,”1 published online on November 18, 2015, and in the January 2016 issue of JAMA Dermatology. We are grateful to Dr Su for his inquiry.
Giamarellos-Bourboulis EJ. The Statistical Significance of the Efficacy Results in a Randomized Clinical Trial—Reply. JAMA Dermatol. 2017;153(9):950. doi:10.1001/jamadermatol.2017.3244
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: